European regulatory authorities approved the Galcanezumab manufacturing and sale for the management of migraine attacks. Migraine is a brain disorder with high disability rates due to the sequence of irregular neuronal networks, communicating at varying levels of the peripheral and central nervous system. Calcitonin gene-related peptide (CGRP) is broadly exposed at the peripheral and central nervous system and works as a sensory neurotransmitter, the mediator of neurogenic inflammation, vasodilator, and can be implicated in the pathophysiology of migraine.

The range of possible therapies for migraine prevention has developed over time. Galcanezumab is a monoclonal antibody particular for the CGRP protein, a vital protein for cluster headache and migraine development. The patients can self-administrate the Galcanezumab injection once a month. Most of the migraineurs exhibited a 50% reduction in the migraine frequency by having the course of Galcanezumab. Moreover, more than one-third of CI participants showed a 72% reduction in the number of attacks as compared to 18% in the placebo group.